Revvity (RVTY) AI Stock Analysis

Revvity

(BMV:RVTY)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Diagnostics growthDiagnostics is showing broad, sustained demand across reproductive health and immunodiagnostics, providing a durable growth engine within the portfolio. This strength can support recurring testing-related consumables and services while offsetting weaker areas of the business.

Negative Factors

Margin compression and earnings volatilityAlthough current profitability is solid, margins remain well below earlier-cycle levels and historical earnings have been uneven. This limits the predictability of long-term earnings power and leaves less operating cushion if demand or business mix becomes less favorable.

Revvity (RVTY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 17.52B
Dividend Yield: 0.18%
Average Volume (3M): ―
Price to Earnings (P/E): 74.8
Beta (1Y): -0.08
Revenue Growth: -5.26%
EPS Growth: -17.75%
Country: Mexico
Employees: 11,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Revvity Business Overview & Revenue Model

Company Description

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters...

Revvity Earnings Call Summary

Earnings Call Date:Aug 03, 2026(Q2-2026)|% Change Since:0.00%|Next Earnings Date:Nov 02, 2026

Earnings Call SentimentPositive

The call presented a generally positive operational and financial picture: revenue and EPS beat with upgraded full-year guidance, strong Diagnostics performance, accelerating high-content instrument orders and robust cash flow and balance sheet improvements. Key near-term weaknesses include a sizable decline in Signals software revenue this quarter, some production/timing constraints that shifted instrument revenue into Q3, and portions of the quarter's outperformance tied to one-time tariff refunds and tax timing. Management plans reinvestments of a portion of one-time benefits while highlighting new software capabilities and AI-driven demand as multi-year growth drivers—though the AI opportunity is still early and not fully quantifiable.

Positive Updates

Top-line and Organic Growth Beat

Q2 pro forma revenue of $711M with 3% pro forma organic growth, slightly above the high end of guidance; full-year organic growth guidance raised to 4%–5% (from 3%–4%).

Negative Updates

Life Sciences Segment Weakness

Life Sciences revenue $359M, organic decline ~3% in Q2 (reported -2%); Life Sciences Solutions modest low-single-digit growth and Signals software declined ~20% year-over-year due to contract timing and difficult comps.

Company Guidance

Revvity raised its 2026 pro forma outlook: organic growth now 4–5% (vs. 3–4%), with FX contributing ~50 bps and the ACD/Labs acquisition ~75 bps, implying pro forma revenue of $2.83–$2.86B; pro forma adjusted operating margin is now 28.7% (up 30 bps) and pro forma adjusted EPS is $5.30–$5.40 (up $0.10), with net interest & other expense ~ $90M, a full‑year tax rate of ~18%, diluted share count ~112M, and a target gross leverage <3x and net leverage approaching 2x by year‑end (net debt/EBITDA was 2.5x at quarter end). For Q3 they guide organic growth of 4–6%, revenue of $685–$700M, ~29% pro forma adjusted operating margin, net interest ~$23M, a Q3 tax rate of ~19% and Q3 EPS ~24% of the full‑year outlook; management noted $16M of tariff refunds in Q2 (about half of Q2 EPS upside) and said most refunds have been received with any additional amounts expected to be immaterial.

Revvity Risk Analysis

Revvity disclosed 24 risk factors in its most recent earnings report. Revvity reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Revvity Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:RVTY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QGEN	80Outperform	$10.37B	25.75	11.60%	5.26%	2.96%	9.52%
TMO	77Outperform	$257.71B	36.70	13.31%	0.26%	8.27%	9.59%
ILMN	76Outperform	$35.63B	40.07	31.45%	―	6.00%	31.48%
A	75Outperform	$49.30B	34.35	20.47%	0.58%	8.60%	19.07%
DHR	73Outperform	$163.38B	37.95	8.18%	0.65%	5.52%	25.53%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:RVTY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:RVTY	Revvity, Inc.	1910.00	163.30	9.35%
A	Agilent Technologies	174.87	31.26	21.77%
DHR	Danaher Corporation	232.23	19.74	9.29%
ILMN	Illumina	235.99	116.00	96.67%
QGEN	Qiagen	50.22	4.87	10.75%
TMO	Thermo Fisher Scientific	697.00	134.10	23.82%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Revvity AI Stock Analysis